Search

Displaying results 2121 - 2130 of 7498 in total
  1. Drug

    Aminophenazone

    go.drugbank.com/drugs/DB01424
    ApprovedWithdrawn

    The FDA suspended the use of aminophenazone due to its association with agranulocytosis, a life-threatening side effect.[A254242,L43942] … In biomedical applications, radiolabelled (13C-labeled) aminophenazone has been used in breath tests to measure the cytochrome P-450 metabolic activity in liver function tests.

    Categories: Non COX-2 selective NSAIDS, Anti-Inflammatory Agents, Non-Steroidal
  2. Drug

    Lymecycline

    go.drugbank.com/drugs/DB00256
    ApprovedInvestigationalWithdrawn

    It is marketed by Galderma and used in the UK as well as New Zealand in addition to other countries. … Lymecycline is not marketed in the USA, however, equivalent drugs are available, such as minocycline and [tetracycline].[A19429,L13880]

    Synonyms: N-Lysinomethyltetracycline, N2-(((+)-5-Amino-5-carboxypentylamino)methyl)tetracycline
  3. Drug

    Enlicitide

    go.drugbank.com/drugs/DB22580
    ApprovedInvestigational

    [L63795] Adverse reaction frequencies were similar to placebo and the drug carries no contraindications. … (CORALreef Lipids), and by 59% in patients with HeFH (CORALreef HeFH), with comparable reductions in non-HDL-C and apolipoprotein B.

  4. Drug

    Cilnidipine

    go.drugbank.com/drugs/DB09232
    Investigational

    It was jointly developed by Fuji Viscera Pharmaceutical Company, Japan and Ajinomoto, Japan and approved in 1995. … Compared with other calcium antagonists, cilnidipine can act on the N-type calcium channel that existing sympathetic nerve end besides acting on L-type calcium channel that similar to most of the calcium

  5. Drug

    Apalutamide

    go.drugbank.com/drugs/DB11901
    ApprovedInvestigational

    Apalutamide was approved in February 2018 by the FDA as Erleada for the treatment of patients with non-metastatic prostate cancer that is resistant to treatment with hormone therapy (castration-resistant … Approximately 10 to 20 % of prostate cancer cases are castration-resistant, and up to 16% of these patients show no evidence of cancer metastasis at the time of castration-resistant diagnosis [L1295].

  6. Drug

    Agalsidase alfa

    go.drugbank.com/drugs/DB15874
    ApprovedInvestigational

    While patients generally do not experience a clinically significant difference in outcomes between the two drugs, some patients may experience greater benefit with agalsidase beta. … Agalsidase alfa is a recombinant human α-galactosidase A similar to [agalsidase beta].

  7. Drug

    Hyaluronidase (ovine)

    go.drugbank.com/drugs/DB00070
    Approved

    Highly purified sheep hyaluronidase for administration by injection into the vitreous of the eye.

  8. Drug

    Nitrous acid

    go.drugbank.com/drugs/DB09112
    ApprovedInvestigational

    Nitrous acid (as sodium nitrite) is used as part of an intravenous mixture with sodium thiosulfate to treat cyanide poisoning. … It is on the World Health Organization's List of Essential Medicines, a list of the most important medications needed in a basic health system.

  9. Drug

    Tegaserod

    go.drugbank.com/drugs/DB01079
    ApprovedWithdrawn

    [L5918,F4229] Zelnorm (tegaserod) by Sloan Pharma subsequently gained re-approval in April of 2019.[L5918] Nevertheless, tegaserod remains un-approved in certain regions. … cardiovascular risk have resulted in the limited reintroduction or 're-approval' of tegaserod for treatment of IBS-C specifically in female patients less than 65 years of age and whom are considered to

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  10. Drug

    Sodium lauryl sulfoacetate

    go.drugbank.com/drugs/DB13157
    ApprovedWithdrawn

    Sodium lauryl sulfoacetate is a wetting agent and surfactant used in enema-type laxative products.